Recent advances of highly selective CDK4/6 inhibitors in breast cancer

Molecular portraits of human breast tumours

Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551 · see citing works

Cancer Statistics, 2017.

Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712 · see citing works

Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer

Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239 · see citing works

Cancer Cell Cycles

Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379 · see citing works

Ki67 expression in breast cancer

Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382 · see citing works

Cell cycle, CDKs and cancer: a changing paradigm

Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · see citing works

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.

Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · see citing works

Palbociclib and letrozole in advanced breast cancer

Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007 · see citing works

Drug delivery with carbon nanotubes for in vivo cancer treatment

Liu, Z., Chen, K., Davis, C. R., Sherlock, S. P., Cao, Q., Chen, X. S., & Dai, H. (2008) · PubMed · doi:10.48550/arxiv.0808.2070 · Cited by 2,287 · see citing works

Ribociclib as first-line therapy for HR-positive, advanced breast cancer

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039 · see citing works

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900 · see citing works

The history and future of targeting cyclin-dependent kinases in cancer therapy

Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767 · see citing works

Palbociclib in hormone-receptor-positive advanced breast cancer

Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590 · see citing works

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398 · see citing works

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts

Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 3× · see citing works

Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment

Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036 · see citing works

Emerging roles of E2Fs in cancer: an exit from cell cycle control

Chen, H., Tsai, S., & Leone, G. W. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2696 · Cited by 1,019 · see citing works

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743 · see citing works

EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition

中川, 学. (2014) · Institutional Repositories DataBase (IRDB) · Cited by 736 · see citing works

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0120-7 · Cited by 577 · see citing works

A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells

Anders, L., Ke, N., Hydbring, P., Choi, Y. J., Widlund, H. R., Chick, J. M., Zhai, H., Vidal, M., Gygi, S. P., Braun, P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.001 · Cited by 543 · see citing works

Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

Carlson, B. A., Dubay, M., Sausville, E. A., Brizuela, L., & Worland, P. J. (1996) · PubMed · Cited by 530 · see citing works

Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a

Russo, A. A., Tong, L., Lee, J.-O., Jeffrey, P. D., & Pavletich, N. P. (1998) · Nature · doi:10.1038/26155 · Cited by 524 · see citing works

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6

Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049354h · Cited by 513 · see citing works

Targeting CDK4/6 in patients with cancer

Hamilton, E. P., & Infante, J. R. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.002 · Cited by 486 · see citing works

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors

Goel, S., Wang, Q., Watt, A. C., Tolaney, S. M., Dillon, D. A., Li, W., Ramm, S., Palmer, A. C., Yuzugullu, H., Varadan, V., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.006 · Cited by 470 · see citing works

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors

Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.020 · Cited by 438 · see citing works

A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma

Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415 · see citing works

Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment

VanArsdale, T., Boshoff, C., Arndt, K. T., & Abraham, R. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0816 · Cited by 396 · see citing works

Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

Rader, J., Russell, M. R., Hart, L. S., Nakazawa, M. S., Belcastro, L. T., Martinez, D., Li, Y., Carpenter, E. L., Attiyeh, E. F., Diskin, S. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1675 · Cited by 394 · see citing works

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure

Dean, J. L., Thangavel, C., McClendon, A. K., Reed, C. A., & Knudsen, E. S. (2010) · Oncogene · doi:10.1038/onc.2010.154 · Cited by 393 · see citing works

Driving the cell cycle with a minimal CDK control network

Coudreuse, D. Y. M., & Nurse, P. (2010) · Nature · doi:10.1038/nature09543 · Cited by 390 · see citing works

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

Flaherty, K. T., LoRusso, P. M., DeMichele, A., Abramson, V. G., Courtney, R., Randolph, S. S., Shaik, M. N., Wilner, K. D., O'Dwyer, P. J., & Schwartz, G. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0509 · Cited by 366 · see citing works

CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment

DeMichele, A., Clark, A. S., Tan, K. S., Heitjan, D. F., Gramlich, K., Gallagher, M., Lal, P., Feldman, M., Zhang, P., Colameco, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2258 · Cited by 343 · see citing works

The Requirement for Cyclin D Function in Tumor Maintenance

Choi, Y. J., Li, X., Hydbring, P., Sanda, T., Stefano, J., Christie, A. L., Signoretti, S., Look, A. T., Kung, A. L., von Boehmer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.015 · Cited by 342 · see citing works

Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts

Michaud, K., Solomon, D. A., Oermann, E. K., Kim, J.-S., Zhong, W.-Z., Prados, M. D., Ozawa, T., James, C. D., & Waldman, T. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4559 · Cited by 321 · see citing works

A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas

Infante, J. R., Cassier, P. A., Gerecitano, J. F., Witteveen, P. O., Chugh, R. K., Ribrag, V., Chakraborty, A., Matano, A., Dobson, J. R., Crystal, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1248 · Cited by 315 · see citing works

Chimeric antigen receptor T cells: a novel therapy for solid tumors

Yu, S., Li, A., Liu, Q., Li, T., Yuan, X., Han, X., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0444-9 · Cited by 306 · see citing works

Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer

Konecny, G. E., Winterhoff, B. J. N., Kolarova, T. R., Qi, J., Manivong, K., Dering, J., Yang, G., Chalukya, M., Wang, H.-J., Anderson, L. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2307 · Cited by 303 · see citing works

The meaning of p16^ink4aexpression in tumors: Functional significance, clinical associations and future developments

Witkiewicz, A. K., Knudsen, K. E., Dicker, A. P., & Knudsen, E. S. (2011) · Cell Cycle · doi:10.4161/cc.10.15.16776 · Cited by 286 · see citing works

Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft

Raub, T. J., Wishart, G. N., Kulanthaivel, P., Staton, B. A., Ajamie, R. T., Sawada, G. A., Gelbert, L. M., Shannon, H. E., Sanchez-Martinez, C., & De Dios, A. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062745 · Cited by 284 · see citing works

Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy

Sedlacek, H., Czech, J., Naik, R., Kaur, G., Worland, P., Losiewicz, M., Parker, B., Carlson, B., Smith, A., Senderowicz, A., et al. (1996) · International Journal of Oncology · doi:10.3892/ijo.9.6.1143 · Cited by 275 · see citing works

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

Schwartz, G. K., LoRusso, P. M., Dickson, M. A., Randolph, S. S., Shaik, M. N., Wilner, K. D., Courtney, R., & O'Dwyer, P. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.177 · Cited by 260 · see citing works

Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy

Roberts, P. J., Bisi, J. E., Strum, J. C., Combest, A. J., Darr, D. B., Usary, J. E., Zamboni, W. C., Wong, K.-K., Perou, C. M., & Sharpless, N. E. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs002 · Cited by 255 · see citing works

Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology

Ellis, L. M., & Hicklin, D. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1070 · Cited by 248 · see citing works

Molecular pathways: CDK4 inhibitors for cancer therapy

Dickson, M. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1551 · Cited by 245 · see citing works

Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer

Jansen, V. M., Bhola, N. E., Bauer, J. A., Formisano, L., Lee, K., Hutchinson, K. E., Witkiewicz, A. K., Moore, P. D., Estrada, M. V., Sanchez, V. M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2653 · Cited by 245 · see citing works

Structural basis of inhibition of CDK–cyclin complexes by INK4 inhibitorsPreprint

Jeffrey, P. D., Tong, L., & Pavletich, N. P. (2000) · Genes & Development · doi:10.1101/gad.851100 · Cited by 239 · see citing works

FoxM1, a critical regulator of oxidative stress during oncogenesis

Park, H. J., Carr, J. R., Wang, Z., Nogueira, V., Hay, N., Tyner, A. L., Lau, L. F., Costa, R. H., & Raychaudhuri, P. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.239 · Cited by 234 · see citing works

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors

Dean, J. L., McClendon, A. K., Hickey, T. E., Butler, L. M., Tilley, W. D., Witkiewicz, A. K., & Knudsen, E. S. (2012) · Cell Cycle · doi:10.4161/cc.21195 · Cited by 226 · see citing works

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6

Baughn, L. B., Di Liberto, M., Wu, K., Toogood, P. L., Louie, T., Gottschalk, R., Niesvizky, R., Cho, H., Ely, S., Moore, M. A. S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1098 · Cited by 225 · see citing works

Cyclin-Dependent Kinases

Harper, J. W., & Adams, P. D. (2001) · Chemical Reviews · doi:10.1021/cr0001030 · Cited by 220 · see citing works

Loss of CDKN 2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK 4/6 inhibitor PD 0332991 in melanoma cell lines

Young, R. J., Waldeck, K., Martin, C., Foo, J. H., Cameron, D. P., Kirby, L., Do, H., Mitchell, C., Cullinane, C. M., Liu, W. J., et al. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12228 · Cited by 206 · see citing works

Targeting the RB-E2F pathway in breast cancer

Johnson, J., Thijssen, B., McDermott, U., Garnett, M. J., Wessels, L. F. A., & Bernards, R. (2016) · Oncogene · doi:10.1038/onc.2016.32 · Cited by 198 · see citing works

PD-0332991, a CDK4/6 Inhibitor, Significantly Prolongs Survival in a Genetically Engineered Mouse Model of Brainstem Glioma

Barton, K. L., Misuraca, K. L., Cordero, F. J., Dobrikova, E. Y., Min, H. D., Gromeier, M., Kirsch, D. G., & Becher, O. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077639 · Cited by 163 · see citing works

CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy

McClendon, A. K., Dean, J. L., Rivadeneira, D. B., Yu, J. E., Reed, C. A., Gao, E., Farber, J. L., Force, T. L., Koch, W. J., & Knudsen, E. S. (2012) · Cell Cycle · doi:10.4161/cc.21127 · Cited by 163 · see citing works

Cyclin-dependent kinase inhibitor therapy for hematologic malignancies

Bose, P., Simmons, G. L., & Grant, S. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.789859 · Cited by 154 · see citing works

Pyrido[2,3- d ]pyrimidin-7-ones as Specific Inhibitors of Cyclin-Dependent Kinase 4

VanderWel, S. N., Harvey, P. J., McNamara, D. J., Repine, J. T., Keller, P. R., Quin, J., Booth, R. J., Elliott, W. L., Dobrusin, E. M., Fry, D. W., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049355+ · Cited by 152 · see citing works

Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity

Marzec, M., Kasprzycka, M., Lai, R. L., Gladden, A. B., Wlodarski, P. K., Tomczak, E. Z., Nowell̀, P. C., DePrimo, S. E., Sadis, S., Eck, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-016634 · Cited by 143 · see citing works

Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level

Song, D.-G., Ye, Q., Poussin, M., Chacon, J. A., Figini, M., & Powell, D. J. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0285-y · Cited by 141 · see citing works

Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status

Kèlland, L. R. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.12.2903 · Cited by 134 · see citing works

The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation

Yadav, V., Burke, T. F., Huber, L., Van Horn, R. D., Zhang, Y., Buchanan, S. G., Chan, E. M., Starling, J. J., Beckmann, R. P., & Peng, S.-B. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0257 · Cited by 132 · see citing works

Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts

Tate, S. C., Cai, S., Ajamie, R. T., Burke, T., Beckmann, R. P., Chan, E. M., De Dios, A., Wishart, G. N., Gelbert, L. M., & Cronier, D. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2846 · Cited by 130 · see citing works

Cdk4/6 Inhibition Induces Epithelial–Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer Cells

Liu, F., & Korc, M. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0562 · Cited by 128 · see citing works

Proliferative Suppression by CDK4/6 Inhibition: Complex Function of the Retinoblastoma Pathway in Liver Tissue and Hepatoma Cells

Rivadeneira, D. B., Mayhew, C. N., Thangavel, C., Sotillo, E., Reed, C. A., Graña, X., & Knudsen, E. S. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.007 · Cited by 127 · see citing works

Antiproliferative Effects of CDK4/6 Inhibition in <i>CDK4</i> -Amplified Human Liposarcoma <i>In Vitro</i> and <i>In Vivo</i>

Zhang, Y.-X., Sicinska, E., Czaplinski, J. T., Remillard, S. P., Moss, S., Wang, Y., Brain, C., Loo, A., Snyder, E. L., Demetri, G. D., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0387 · Cited by 114 · see citing works

Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer

Barroso‐Sousa, R., Shapiro, G. I., & Tolaney, S. M. (2016) · Breast Care · doi:10.1159/000447284 · Cited by 113 · see citing works

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

Ozaki, A., Tanimoto, T., & Saji, S. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1510345 · Cited by 102 · see citing works

PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.

Logan, J. E., Mostofizadeh, N., Desai, A. J., von Euw, E., Conklin, D. F., Konkankit, V., Hamidi, H., Eckardt, M. A., Anderson, L. A., Chen, H., et al. (2013) · PubMed · Cited by 101 · see citing works

Attenuation of the Retinoblastoma Pathway in Pancreatic Neuroendocrine Tumors Due to Increased Cdk4/Cdk6

Tang, L. H., Contractor, T., Clausen, R., Klimstra, D. S., Du, Y. N., Allen, P. J., Brennan, M. F., Levine, A. J., & Harris, C. R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3264 · Cited by 99 · see citing works

Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma

Wood, A., Krytska, K., Ryles, H. T., Infarinato, N. R., Sano, R., Hansel, T. D., Hart, L. S., King, F. J., Smith, T. R., Ainscow, E., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1114 · Cited by 98 · see citing works

FoxM1c Counteracts Oxidative Stress-induced Senescence and Stimulates Bmi-1 Expression

Li, S. K. M., Smith, D. K., Leung, W. Y., Cheung, A. M. S., Lam, E. W. ‐., Dimri, G. P., & Yao, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709604200 · Cited by 97 · see citing works

Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients

Tamura, K., Mukai, H., Naito, Y., Yonemori, K., Kodaira, M., Tanabe, Y., Yamamoto, N., Osera, S., Sasaki, M., Mori, Y., et al. (2016) · Cancer Science · doi:10.1111/cas.12932 · Cited by 92 · see citing works

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

Sun, W., Yuan, X., Tian, Y., Wu, H. K., Xu, H., Hu, G., & Wu, K. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0193-6 · Cited by 86 · see citing works

Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs

Knutson, T. P., Truong, T. H., Ma, S., Brady, N. J., Sullivan, M. E., Raj, G. V., Schwertfeger, K. L., & Lange, C. A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0462-7 · Cited by 86 · see citing works

Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma

Hart, L. S., Rader, J., Raman, P., Batra, V., Russell, M. R., Tsang, M., Gagliardi, M. E., Chen, L. L., Martínez, D., Li, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1131 · Cited by 81 · see citing works

The cell cycle

Hunt, T., Nasmyth, K., & Novák, B. (2011) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2011.0274 · Cited by 76 · see citing works

CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer

Xu, H., Wu, K., Tian, Y., Liu, Q., Han, N., Yuan, X., Zhang, L., Wu, G. S., & Wu, K. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3639 · Cited by 74 · see citing works

Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer

Lu, J. M. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0194-5 · Cited by 69 · see citing works

Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells

Whiteway, S. L., Harris, P. S., Venkataraman, S., Alimova, I. N., Birks, D. K., Donson, A. M., Foreman, N. K., & Vibhakar, R. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-1000-7 · Cited by 67 · see citing works

An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing

Aoki, Y., Hashizume, R., Ozawa, T., Banerjee, A., Prados, M. D., James, C. D., & Gupta, N. M. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0796-x · Cited by 63 · see citing works

Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer

Fujiwara, Y., Tamura, K., Kondo, S., Tanabe, Y., Iwasa, S., Shimomura, A., Kitano, S., Ogasawara, K., Turner, P. K., Mori, J., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3085-8 · Cited by 62 · see citing works

CDK4/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1

Sathe, A., Koshy, N. R., Schmid, S. C., Thalgott, M. K., Schwarzenböck, S. M., Krause, B. J., Holm, P. S., Gschwend, J. E., Retz, M. M., & Nawroth, R. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.08.082 · Cited by 61 · see citing works

The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer

Shah, A. N., & Cristofanilli, M. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0443-7 · Cited by 60 · see citing works

Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.

Wu, K., Wang, C., D’Amico, M., Lee, R. J., Albanese, C., Pestell, R. G., & Mani, S. (2002) · PubMed · Cited by 59 · see citing works

The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma

Ku, B. M., Yi, S. Y., Koh, J., Bae, Y.-H., Sun, J., Lee, S., Ahn, J. S., Park, K., & Ahn, M. (2016) · Oncotarget · doi:10.18632/oncotarget.7543 · Cited by 57 · see citing works

Early G1 Cyclin-Dependent Kinases as Prognostic Markers and Potential Therapeutic Targets in Esophageal Adenocarcinoma

Ismail, A., Bandla, S., Réveiller, M., Toia, L. M., Zhou, Z., Gooding, W. E., Kalatskaya, I., Stein, L. D., D’Souza, M., Litle, V. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0244 · Cited by 54 · see citing works

Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation

Wang, S., Su, X., Bai, H., Zhao, J., Duan, J., An, T., Zhuo, M., Wang, Z., Wu, M., Li, Z., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0210-9 · Cited by 52 · see citing works

Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo

Wu, T., Chen, Z., To, K. K. W., Fang, X., Wang, F., Cheng, B., & Fu, L. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.10.015 · Cited by 52 · see citing works

The Role of Controlled Proteolysis in Cell‐Cycle Regulation

Udvardy, A. (1996) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1996.0307h.x · Cited by 47 · see citing works

Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol

Mahoney, E., Byrd, J. C., & Johnson, A. J. (2013) · Autophagy · doi:10.4161/auto.23027 · Cited by 41 · see citing works

Expression profile of SIX family members correlates with clinic-pathological features and prognosis of breast cancer

Xu, H.-X., Wu, K.-J., Tian, Y., Liu, Q., Han, N., He, X.-L., Yuan, X., Wu, G. S., & Wu, K.-M. (2016) · Medicine · doi:10.1097/md.0000000000004085 · Cited by 41 · see citing works

Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis

Lauro, L. D., Pizzuti, L., Barba, M., Sergi, D., Sperduti, I., Mottolese, M., Amoreo, C. A., Belli, F., Vici, P., Speirs, V., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0147-z · Cited by 40 · see citing works

Molecular mechanism of G1 arrest and cellular senescence induced by LEE011, a novel CDK4/CDK6 inhibitor, in leukemia cells

Tao, Y., Wang, N., Xu, L., Li, Z., Li, X., Xu, Y., Fang, F., Li, M., Qian, G., Li, Y., et al. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0405-y · Cited by 40 · see citing works

Specific CDK4/6 inhibition in breast cancer: a systematic review of current clinical evidence

Dyhl-Polk, A., Kolmos, I. L., Kümler, I., & Nielsen, D. L. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000093 · Cited by 39 · see citing works

Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients

Zhang, P., Tong, Z., Tian, F., Wang, Y., Yang, J., Li, W., Di, L., Liu, W. Y., Tang, L., Qiu, R., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0297-7 · Cited by 33 · see citing works

EPCR promotes breast cancer progression by altering SPOCK1/testican 1-mediated 3D growth

Perurena, N., Zandueta, C., Martínez-Canarias, S., Moreno, H., Vicent, S., Almeida, A. S., Guruceaga, E., Gomis, R. R., Santisteban, M., Egeblad, M., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0399-x · Cited by 27 · see citing works

Sampling circulating tumor cells for clinical benefits: how frequent?

Leong, S. M., Tan, K. M. L., Chua, H. W., Tan, D. S. W., Jumaat, D. F., Osmany, S., Li, M., Tucker, S. J., & Koay, E. S. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0174-9 · Cited by 24 · see citing works

The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro

Prada, E. T. A., Nölting, S., Spoettl, G., Maurer, J., & Auernhammer, C. J. (2017) · Neuroendocrinology · doi:10.1159/000463386 · Cited by 24 · see citing works

Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel

Trapé, A. P., Liu, S., Cortés, A. C., Ueno, N. T., & Gonzalez-Angulo, A. M. (2016) · Journal of Cancer · doi:10.7150/jca.14441 · Cited by 11 · see citing works

Les inhibiteurs du cycle cellulaire et cancer du sein hormonodépendant

Sablin, M., Ricci, F., Loirat, D., Jobard, A., Basse, C., Romano, E., Tourneau, C. L., & Dieras, V. C. (2017) · Bulletin du Cancer · doi:10.1016/j.bulcan.2016.12.005 · Cited by 8 · see citing works

213Bi (Alpha-emitter)-Antibody Targeting of Breast Cancer Metastases in the neu-N Transgenic Mouse Model

Bobisse, S., Rondina, M., Merlo, A., et al. (2008) · Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) · doi:10.1158/0008-5472 · Cited by 1 · see citing works

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works

Oral mucositis: the hidden side of cancer therapy

Pulito, C., Cristaudo, A., Porta, C. A. M. L., Zapperi, S., Blandino, G., Morrone, A., & Strano, S. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01715-7 · Cited by 557 · see citing works

Recent Advances in the Treatment of Breast Cancer

Tong, C. W. S., Wu, M., Cho, W. C. S., & To, K. K. W. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00227 · Cited by 407 · see citing works

Organoid technology and applications in cancer research

Xu, H., Lyu, X., Yi, M., Zhao, W., Song, Y., & Wu, K. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0662-9 · Cited by 350 · see citing works

Chemistries of bifunctional PROTAC degraders

Cao, C., He, M., Wang, L., He, Y., & Rao, Y. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00220e · Cited by 313 · see citing works

Current State of Breast Cancer Diagnosis, Treatment, and Theranostics

Bhushan, A., Gonsalves, A., & Menon, J. U. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050723 · Cited by 316 · see citing works

Shear-induced Notch-Cx37-p27 axis arrests endothelial cell cycle to enable arterial specification

Fang, J. S., Coon, B. G., Gillis, N. E., Chen, Z., Qiu, J., Chittenden, T. W., Burt, J. M., Schwartz, M. A., & Hirschi, K. K. (2017) · Nature Communications · doi:10.1038/s41467-017-01742-7 · Cited by 281 · see citing works

Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer

Zhang, H., Pandey, S., Travers, M. E., Sun, H., Morton, G. C., Madžo, J., Chung, W., Khowsathit, J., Pérez, Ó. C., Barrero, C. A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.051 · Cited by 218 · see citing works

Mechanisms for estrogen receptor expression in human cancer

Hua, H. M., Zhang, H., Kong, Q., & Jiang, Y. (2018) · Experimental Hematology and Oncology · doi:10.1186/s40164-018-0116-7 · Cited by 222 · see citing works

Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors

Piezzo, M., Cocco, S., Caputo, R., Cianniello, D., Gioia, G. D., Lauro, V. D., Fusco, G., Martinelli, C., Nuzzo, F., Pensabene, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186479 · Cited by 204 · see citing works

Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside

Basile, D., Nardo, P. D., Corvaja, C., Garattini, S. K., Pelizzari, G., Lisanti, C., Bortot, L., Ros, L. D., Bartoletti, M., Borghi, M., et al. (2019) · Cancers · doi:10.3390/cancers11060857 · Cited by 138 · see citing works

Breast cancer: The translation of big genomic data to cancer precision medicine

Low, S., Zembutsu, H., & Nakamura, Y. (2017) · Cancer Science · doi:10.1111/cas.13463 · Cited by 136 · see citing works

PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer

Zhao, B., & Burgess, K. (2019) · Chemical Communications · doi:10.1039/c9cc00163h · Cited by 130 · see citing works

Microneedle Patch Delivery of PROTACs for Anti-Cancer Therapy

Cheng, X., Hu, S., & Cheng, K. (2023) · ACS Nano · doi:10.1021/acsnano.3c03166 · Cited by 119 · see citing works

Abemaciclib: First Global Approval

Kim, E. (2017) · Drugs · doi:10.1007/s40265-017-0840-z · Cited by 117 · see citing works

Transposable element regulation and expression in cancer

Grundy, E. E., Diab, N., & Chiappinelli, K. B. (2021) · FEBS Journal · doi:10.1111/febs.15722 · Cited by 113 · see citing works

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

Laroche-Clary, A., Chaire, V., Algeo, M.-P., Derieppe, M.-A., Loarer, F. L., & Italiano, A. (2017) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-017-0482-3 · Cited by 111 · see citing works

Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures

Cheng, W., Yang, Z., Wang, S., Li, Y., Han, W., Tian, X., & Kan, Q. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.003 · Cited by 111 · see citing works

Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies

Niu, Y., Xu, J., & Sun, T. (2019) · Journal of Cancer · doi:10.7150/jca.32628 · Cited by 98 · see citing works

The roles of exosomes in cancer drug resistance and its therapeutic application

Li, S., Yi, M., Dong, B., Jiao, Y., Luo, S., & Wu, K. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.257 · Cited by 96 · see citing works

Patient-derived organoids in human cancer: a platform for fundamental research and precision medicine

Qu, S., Xu, R., Yi, G., Li, Z., Zhang, H., Qi, S., & Huang, G. (2024) · Molecular Biomedicine · doi:10.1186/s43556-023-00165-9 · Cited by 98 · see citing works

The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma

García-Reyes, B., Kretz, A.-L., Ruff, J.-P., von Karstedt, S., Hillenbrand, A., Knippschild, U., Henne‐Bruns, D., & Lemke, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103219 · Cited by 90 · see citing works

Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer

Frame, S., Saladino, C., MacKay, C., Atrash, B., Sheldrake, P. W., McDonald, E., Clarke, P. A., Workman, P., Blake, D., & Zheleva, D. I. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234103 · Cited by 94 · see citing works

Androgen receptor in estrogen receptor positive breast cancer: Beyond expression

Basile, D., Cinausero, M., Iacono, D., Pelizzari, G., Bonotto, M., Vitale, M. G., Gerratana, L., & Puglisi, F. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.09.006 · Cited by 80 · see citing works

CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib

Laderian, B., & Fojo, T. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.03.006 · Cited by 77 · see citing works

Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer

D'souza, A., SPICER, D. V., & Lu, J. M. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0620-6 · Cited by 74 · see citing works

Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy

Jiao, X., Wang, M., Zhang, Z., Li, Z., Ni, D., Ashton, A. W., Tang, H., Speicher, D. W., & Pestell, R. G. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01391-1 · Cited by 70 · see citing works

The Renaissance of Cyclin Dependent Kinase Inhibitors

Ettl, T., Schulz, D., & Bauer, R. J. (2022) · Cancers · doi:10.3390/cancers14020293 · Cited by 71 · see citing works

CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells

Zhang, L., Li, Y., Hu, C., Chen, Y., Chen, Z., Chen, Z., Zhang, J., & Fang, S. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01524-w · Cited by 68 · see citing works

Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells

Gupta, P., Zhang, Y., Zhang, X., Wang, Y., Lu, K. W., Hall, T., Peng, R., Yang, D., Xie, N., & Chen, Z. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000487578 · Cited by 67 · see citing works

EZH2-, CHD4-, and IDH-linked epigenetic perturbation and its association with survival in glioma patients

Zhang, L., Liu, Y., Wang, M., Wu, Z., Li, N., Zhang, J., & Yang, C. (2017) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjx056 · Cited by 65 · see citing works

Targeting stem cells in the realm of drug-resistant breast cancer

Dey, P., Rathod, M., & De, A. (2019) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s189224 · Cited by 64 · see citing works

Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review

Husna, S. M. N., Tan, H. T., Mohamud, R., Dyhl-Polk, A., & Wong, K. K. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918808509 · Cited by 58 · see citing works

Advances of Targeted Therapy for Hepatocellular Carcinoma

Niu, M., Yi, M., Li, N., Wu, K., & Wu, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719896 · Cited by 57 · see citing works

Latest Overview of the Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: The Past, the Present and the Future

Chen, X., Xu, D., Li, X., Zhang, J., Xu, W., Hou, J., Zhang, W., & Tang, J. (2019) · Journal of Cancer · doi:10.7150/jca.33079 · Cited by 53 · see citing works

DACH1 suppresses breast cancer as a negative regulator of CD44

Xu, H., Yu, S., Yuan, X., Xiong, J., Kuang, D., Pestell, R. G., & Wu, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-04709-2 · Cited by 46 · see citing works

Treatment for the endocrine resistant breast cancer: Current options and future perspectives

Liu, C., Wu, C., Petrossian, K., Huang, T., Tseng, L., & Chen, S. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.07.001 · Cited by 46 · see citing works

The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance

Abdelmalak, M., Singh, R., Anwer, M. I., Ivanchenko, P., Randhawa, A., Ahmed, M., Ashton, A. W., Du, Y., Jiao, X., & Pestell, R. G. (2022) · Cancers · doi:10.3390/cancers14215388 · Cited by 45 · see citing works

Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG)

The Breast Cancer Therapy Expert Group (BCTEG), Abraham, J., Coleman, R. E., ELIAS, A. D., Holmes, F. A., Kalinsky, K. M., Kittaneh, M., Lower, E. E., Mahtani, R. L., Mamounas, E., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4783-1 · Cited by 44 · see citing works

Combination Therapy and Nanoparticulate Systems: Smart Approaches for the Effective Treatment of Breast Cancer

Gadag, S., Sinha, S., Nayak, Y., Garg, S., & Nayak, U. Y. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060524 · Cited by 46 · see citing works

Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials

Ramos-Esquivel, A., Hernández-Steller, H., Savard, M.-F., & Landaverde, D. (2018) · Breast Cancer · doi:10.1007/s12282-018-0848-6 · Cited by 42 · see citing works

Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects

Pineda, E., Doménech, M., Hernández, A., Comas, S., & Balañá, C. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s366371 · Cited by 40 · see citing works

Gastrointestinal adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: a systematic review and meta-analysis

Shohdy, K. S., Lasheen, S., Kassem, L. M. H., & Abdel-Rahman, O. M. (2017) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098617722516 · Cited by 40 · see citing works

Profile of abemaciclib and its potential in the treatment of breast cancer

Martin, J., & Goldstein, L. J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s149245 · Cited by 40 · see citing works

Hormone-induced DNA damage response and repair mediated by cyclin D1 in breast and prostate cancer

Sante, G. D., Rocco, A. D., Pupo, C., Casimiro, M. C., & Pestell, R. G. (2017) · Oncotarget · doi:10.18632/oncotarget.19413 · Cited by 38 · see citing works

SIRT7 depletion inhibits cell proliferation, migration, and increases drug sensitivity by activating p38MAPK in breast cancer cells

Chen, K., Li, L., Yang, F., Li, C., Wang, Y., & Wang, G. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26398 · Cited by 38 · see citing works

Biology of Cancer; From Cellular Cancerogenesis to Supracellular Evolution of Malignant Phenotype

Motofei, I. G. (2018) · Cancer Investigation · doi:10.1080/07357907.2018.1477955 · Cited by 38 · see citing works

Quadruple-negative breast cancer: novel implications for a new disease

Bhattarai, S., Saini, G., Gogineni, K., & Aneja, R. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01369-5 · Cited by 38 · see citing works

Two Novel Palbociclib-Resorcinol and Palbociclib-Orcinol Cocrystals with Enhanced Solubility and Dissolution Rate

Duan, C., Liu, W., Tao, P., Liang, F., Chen, Y., Xiao, X., Zhang, G., Chen, Y., & Hao, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010023 · Cited by 37 · see citing works

Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis

Becherini, C., Visani, L., Caini, S., Bhattacharya, I. S., Kirby, A. M., Marta, G. N., Morgan, G., Salvestrini, V., Coles, C. E., Cortés, J., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102586 · Cited by 38 · see citing works

Clinicopathological and prognostic significance of SDC1 overexpression in breast cancer

Cui, X., Jing, X., Yi, Q., Long, C., Tian, J., & Zhu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.22820 · Cited by 35 · see citing works

Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women

Cersosimo, R. J. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz121 · Cited by 35 · see citing works

Targeting CDK7 in oncology: The avenue forward

Li, Z., Liu, G., Gao, Y., & Zhao, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108229 · Cited by 34 · see citing works

Overexpression of CLEC3A promotes tumor progression and poor prognosis in breast invasive ductal cancer

Ni, J., Peng, Y., Yang, F., Xi, X., Huang, X., & He, C. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s161311 · Cited by 33 · see citing works

Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology

Sante, G. D., Pagé, J., Jiao, X., Nawab, O., Cristofanilli, M., Skordalakes, E., & Pestell, R. G. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1615889 · Cited by 32 · see citing works

Cyclin-Dependent Kinase 4/6 Inhibitors Combined With Radiotherapy for Patients With Metastatic Breast Cancer

Ratoša, I., Oražem, M., Scoccimarro, E., Steinacher, M., Dominici, L., Aquilano, M., Cerbai, C., Desideri, I., Ribnikar, D., Marinko, T., et al. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.05.013 · Cited by 31 · see citing works

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017

Uitdehaag, J. C. M., Kooijman, J. J., de Roos, J. A. D. M., Prinsen, M. B. W., Dylus, J., Willemsen‐Seegers, N., Kawase, Y., Sawa, M., de Man, J., van Gerwen, S. J. C., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0877 · Cited by 30 · see citing works

Malignant Melanoma: Autoimmunity and Supracellular Messaging as New Therapeutic Approaches

Motofei, I. G. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0643-4 · Cited by 30 · see citing works

CDK4-6 inhibitors in breast cancer: current status and future development

Choo, J. R.-E., & Lee, S. C. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1541347 · Cited by 29 · see citing works

RDGN-based predictive model for the prognosis of breast cancer

Dong, B., Yi, M., Luo, S., Li, A., & Wu, K. (2020) · Experimental Hematology and Oncology · doi:10.1186/s40164-020-00169-z · Cited by 29 · see citing works

CDK Inhibitors as Sensitizing Agents for Cancer Chemotherapy

Gupta, P., Narayanan, S., & Yang, D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816435-8.00009-2 · Cited by 27 · see citing works

Bcl‑2 promotes metastasis through the epithelial‑to‑mesenchymal transition in the BCap37 medullary breast cancer cell line

Du, C., Zhang, X., Yao, M., Lv, K., Wang, J., Chen, L., Chen, Y., Wang, S., & Fu, P. (2018) · Oncology Letters · doi:10.3892/ol.2018.8455 · Cited by 25 · see citing works

Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer

Kurozumi, S., Matsumoto, H., Inoue, K., Tozuka, K., Hayashi, Y., Kurosumi, M., Oyama, T., Fujii, T., Horiguchi, J., & Kuwano, H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201846 · Cited by 25 · see citing works

Melanoma and autoimmunity: spontaneous regressions as a possible model for new therapeutic approaches

Motofei, I. G. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000573 · Cited by 25 · see citing works

EYA2 Correlates With Clinico-Pathological Features of Breast Cancer, Promotes Tumor Proliferation, and Predicts Poor Survival

Xu, H., Jiao, Y., Yi, M., Zhao, W., & Wu, K. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00026 · Cited by 21 · see citing works

Selective CDK4/6 inhibition of novel 1,2,3-triazole tethered acridinedione derivatives induces G1/S cell cycle transition arrest via Rb phosphorylation blockade in breast cancer models

Praveenkumar, E., Gurrapu, N., Kolluri, P. K., Shivaraj, S., Subhashini, N. J. P., & Dokala, A. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105377 · Cited by 19 · see citing works

PARP Pioneers: Using BRCA1/2 Mutation-targeted Inhibition to Revolutionize Breast Cancer Treatment

Sharma, N., Bhati, A., Aggarwal, S., Shah, K., & Dewangan, H. K. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128322894241004051814 · Cited by 18 · see citing works

Identification of the potential crucial genes in invasive ductal carcinoma using bioinformatics analysis

Li, C. G., Luo, L., Wei, S., & Wang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.23239 · Cited by 18 · see citing works

Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre

Twelves, C., Cheeseman, S., Sopwith, W., Thompson, M., Riaz, M., Ahat-Donker, N., Myland, M., Lee, A., Przybysz, R., Turner, S. J., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-6527-y · Cited by 18 · see citing works

Inhibition of the CDK4/6‐Cyclin D‐Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma

Chen, D., Sun, X., Zhang, X., & Cao, J. (2020) · BioMed Research International · doi:10.1155/2020/9525207 · Cited by 18 · see citing works

Efficacy and Safety of Palbociclib in Heavily Pretreated Patients with HR+/HER2- Metastatic Breast Cancer

Ban, M., Miše, B. P., Majić, A., Dražić, I., & Vrdoljak, E. (2017) · Future Oncology · doi:10.2217/fon-2017-0491 · Cited by 17 · see citing works

Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer

Visani, L., Livi, L., Ratoša, I., Oražem, M., Ribnikar, D., Saieva, C., Becherini, C., Salvestrini, V., Scoccimarro, E., Valzano, M., et al. (2022) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2022.10.023 · Cited by 17 · see citing works

The regulatory role of CDK4/6 inhibitors in tumor immunity and the potential value of tumor immunotherapy (Review)

He, F., Zhang, Q., Chen, Y., Ge, S., Xie, Y., Sun, R., Wu, Y., & Xu, J. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5564 · Cited by 16 · see citing works

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study

Tolaney, S. M., Beeram, M., Beck, J. T., Conlin, A. K., Dees, E. C., Puhalla, S. L., Rexer, B. N., Burris, H. A., Jhaveri, K. L., Helsten, T. L., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.810023 · Cited by 16 · see citing works

C4orf19 inhibits colorectal cancer cell proliferation by competitively binding to Keap1 with TRIM25 via the USP17/Elk-1/CDK6 axis

Huang, S., Li, J., Wu, S., Zheng, Z., Wang, C., Li, H., Zhao, L., Zhang, X., Huang, H., Huang, C., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02656-z · Cited by 16 · see citing works

Interleukin-6 Family of Cytokines in Cancers

Zaporowska-Stachowiak, I., Springer, M., Stachowiak-Szymczak, K., Oduah, M.-T. A., Sopata, M., Wieczorowska–Tobis, K., & Bryl, W. (2024) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2023.0103 · Cited by 17 · see citing works

SOCS1 blocks G1-S transition in hepatocellular carcinoma by reducing the stability of the CyclinD1/CDK4 complex in the nucleus

Ding, J., Xu, K., Sun, S., Qian, C., Yin, S., Xie, H., Zhou, L., Zheng, S., & Zhang, W. (2020) · Aging · doi:10.18632/aging.102865 · Cited by 16 · see citing works

Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer

Rugo, H. S., Haltner, A., Zhan, L., Tran, A., Bananis, E., Hooper, B., Mitra, D., & Cameron, C. G. (2021) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2020-0272 · Cited by 16 · see citing works

The CDK4/6 inhibitor in HR-positive advanced breast cancer

Ding, W., Li, Z., Wang, C., Ruan, G., Chen, L., & Tu, C. (2018) · Medicine · doi:10.1097/md.0000000000010746 · Cited by 16 · see citing works

Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer

Howard, D., James, D. H., García-Parra, J., Pan‐Castillo, B., Worthington, J., Williams, N., Coombes, Z., Rees, S. C., Lutchman-Singh, K., Francis, L. W., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1014280 · Cited by 15 · see citing works

QTc prolongation across CDK4/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials

Murad, B., Reis, P. C. A., Marinho, A. D., Comini, A. C. M., Xavier, D. P., Pessoa, B., Raheem, F., Ernst, B. J., Mina, L. A., & Batalini, F. (2024) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkae078 · Cited by 15 · see citing works

Regional Variation in Epidermal Susceptibility to UV-Induced Carcinogenesis Reflects Proliferative Activity of Epidermal Progenitors

Roy, E., Wong, H. Y., Villani, R. M., Rouillé, T., Salik, B., Sim, S.-L., Murigneux, V., Stark, M. S., Fink, J. L., Soyer, H. P., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107702 · Cited by 14 · see citing works

Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer

Hachem, G. E., Gombos, A., & Awada, A. H. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1834385 · Cited by 14 · see citing works

Cyclin-Dependent Kinase 4/6 Inhibitors Against Breast Cancer

Ateş‐Alagöz, Z., & Hassan, M. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557522666220606095540 · Cited by 14 · see citing works

Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer

Hoste, G., Punie, K., Wildiers, H. P. M. W., Beuselinck, B., Lefever, I., Nieuwenhuysen, E. V., Han, S., Berteloot, P., Concin, N., Salihi, R. R., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4827-6 · Cited by 14 · see citing works

Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation

Quan, C., Wu, Z., Xiong, J., Li, M., Fu, Y., Su, J., Wang, Y., Ning, L., Zhang, D., & Xie, N. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00462-7 · Cited by 13 · see citing works

Safety and efficacy profile of cyclin‐dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta‐analysis of clinical trials

Guo, L., Hu, Y., Chen, X., Li, Q., Wei, B., & Ma, X. (2019) · Cancer Medicine · doi:10.1002/cam4.1970 · Cited by 13 · see citing works

Evaluation of the pharmacokinetics of the simultaneous quantification of letrozole and palbociclib in rat plasma by a developed and validated HPLC–PDA

Al-Shehri, M. M., Hefnawy, M., Abuelizz, H. A., & Alzamil, A. (2019) · Acta Chromatographica · doi:10.1556/1326.2019.00635 · Cited by 13 · see citing works

Optimal duration of adjuvant endocrine therapy: how to apply the newest data

Wimmer, K., Kacerovsky-Strobl, S., Bolliger, M. J., Devyatko, Y., Korkmaz, B., Exner, R., Fitzal, F., & Gnant, M. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017732966 · Cited by 12 · see citing works

Efficacy and Safety of Cyclin-Dependent Kinases 4 and 6 Inhibitors in HR+/HER2− Advanced Breast Cancer

Xie, N., Qin, T., Ren, W., Yao, H., Yu, Y., & Hong, H. (2020) · Cancer Management and Research · doi:10.2147/cmar.s254365 · Cited by 12 · see citing works

Palbociclib and letrozole in hormone-receptor positive advanced breast cancer: Predictive response and prognostic factors

Gharib, K. E., Macaron, W., Kattan, J. G., Salloum, M. A., Farhat, F. S., Smith, M. C., & Karak, F. E. (2022) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2022.100859 · Cited by 12 · see citing works

Cancer-testis antigen CEP55 serves as a prognostic biomarker and is correlated with immune infiltration and immunotherapy efficacy in pan-cancer

Xie, X., Liang, H., Jiangting, W., Wang, Y., Ma, X., Tan, Z., Cheng, L., Luo, Z., & Wang, T. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1198557 · Cited by 11 · see citing works

Exploring a Desirable Quadr-mRNAs Panel for Non-invasive and Ultrasensitive Bladder Cancer Diagnosis: In-silico and Clinical Studies

Abazari, O., Dayati, P., Shahidi, M., Reza, J. Z., Rahmanian, M., & Naghib, S. M. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673302140240627053904 · Cited by 11 · see citing works

Emerging treatments and personalised medicine for ciliopathies associated with cystic kidney disease

Molinari, E., & Sayer, J. A. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1372282 · Cited by 11 · see citing works

Cytochrome P450 2U1 Is a Novel Independent Prognostic Biomarker in Breast Cancer Patients

Luo, B., Chen, C., Wu, X., Yan, D., Chen, F., Yu, X., & Yuan, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01379 · Cited by 11 · see citing works

Common targets for a deadly duo of diabetes mellitus and colon cancer: Catching two fish with one worm

Gajjar, S., & Patel, B. M. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173805 · Cited by 11 · see citing works

An Interpretable Multitask Framework BiLAT Enables Accurate Prediction of Cyclin-Dependent Protein Kinase Inhibitors

Xu, Q., Dai, X., Luo, L., Lin, M., Xu, Y., Zhao, Y., Huang, D., Qiu, H., Liang, L., Liu, H., et al. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00473 · Cited by 10 · see citing works

Occurrence of senescence-escaping cells in doxorubicin-induced senescence is enhanced by PD0332991, a cyclin-dependent kinase 4/6 inhibitor, in colon cancer HCT116 cells

Kitada, K., Pu, F., & Toi, M. (2018) · Oncology Letters · doi:10.3892/ol.2018.9657 · Cited by 10 · see citing works

Role of macrophages in cancer progression and targeted immunotherapies

Arora, L., Kalia, M., & Pal, D. (2022) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.11.010 · Cited by 9 · see citing works

Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data

Vidula, N., & Rugo, H. S. (2015) · Clinical Breast Cancer · doi:10.1016/j.clbc.2015.07.005 · Cited by 85 · see citing works

Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib

Kwapisz, D. M. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4385-3 · Cited by 207 · see citing works

Palbociclib, ribociclib, and abemaciclib: potent and selective CDK4/6 inhibitors for the treatment of breast cancer

Yuan, K., Chen, W., Wang, X., & Yang, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00022-4

Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future

Spring, L. M., Wander, S. A., André, F., Moy, B., Turner, N. C., & Bardia, A. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30165-3 · Cited by 482 · see citing works

An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer

Robert, M., Frenel, J., Bourbouloux, E., Rigaud, D. B., Patsouris, A., Augereau, P., Gourmelon, C., & Campone, M. (2018) · Drugs · doi:10.1007/s40265-018-0972-9 · Cited by 13 · see citing works